Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.
Department of Financial Analysis, Johns Hopkins Medical Institutions, Baltimore, MD.
Clin Lung Cancer. 2019 Jul;20(4):e430-e441. doi: 10.1016/j.cllc.2019.02.010. Epub 2019 Mar 12.
National costs of lung cancer care exceed $12 billion. We investigate the resource-savings benefit of a single-day thoracic oncology multidisciplinary clinic (MDC) in the diagnostic period prior to non-small-cell lung cancer (NSCLC) treatment.
From July 2007 to January 2015, patients with NSCLC treated with multimodality therapy at a tertiary hospital-based cancer center in Maryland were identified. Patient and treatment details were collected. Health care resources utilized in the 90 days prior to receipt of first oncologic treatment were identified using billed activity codes. Associated total charges, including professional fees and hospital-based technical fees, were identified and inflated to 2014 dollars using the Consumer Price Index. Codes were categorized into provider visits, procedures, pathology/laboratory, radiology, and other tests. χ, Student t, and Wilcoxon rank-sum tests compared charges of patients seen in and out of the MDC.
Two-hundred ninety-seven (non-MDC = 161, 54%; MDC = 136, 46%) of 308 patients identified had total charges available. Patients seen through MDC had on average a 23% decrease in total charges per patient incurred ($5839 savings; range, $5213-$6464) compared with patients seen through non-MDC settings. Evaluation through MDC reduced the average number of provider visits per patient (non-MDC, 6.8 vs. MDC, 4.8; P < .01) prior to treatment start, which led to a 50% (average $3092; range, $2451-$3732) reduction in provider charges per patient (P < .01).
Evaluation of patients with NSCLC through a coordinated single-day MDC reduced hospital charges per patient by 23% during the diagnostic period prior to treatment when compared with evaluation through traditional referral-based thoracic oncology clinics.
肺癌治疗费用超过 120 亿美元。我们研究了在非小细胞肺癌(NSCLC)治疗前的诊断期内,开设一天制胸外科多学科诊疗(MDC)的节省资源效益。
从 2007 年 7 月至 2015 年 1 月,我们在马里兰州一家基于癌症中心的三级医院治疗的 NSCLC 患者,确定了患者和治疗细节。使用计费活动代码确定了在接受首次肿瘤治疗前的 90 天内利用的医疗资源。确定了与专业费用和医院技术费用相关的总费用,并使用消费者物价指数(CPI)将其膨胀到 2014 年的美元。将代码分为就诊、程序、病理学/实验室、放射学和其他测试。通过 χ²、学生 t 检验和 Wilcoxon 秩和检验比较了 MDC 内外就诊患者的费用。
308 例患者中,有 297 例(非 MDC=161 例,54%;MDC=136 例,46%)的总费用可用。与非 MDC 就诊患者相比,通过 MDC 就诊的患者每人的总费用平均减少了 23%(节省 5839 美元;范围为 5213 美元至 6464 美元)。通过 MDC 评估可减少每位患者治疗前的平均就诊次数(非 MDC,6.8 次;MDC,4.8 次;P<.01),从而使每位患者的就诊费用减少了 50%(平均 3092 美元;范围为 2451 美元至 3732 美元)(P<.01)。
与传统的基于胸外科肿瘤学门诊的就诊方式相比,通过协调的一天制 MDC 对 NSCLC 患者进行评估,可在治疗前的诊断期内,使每位患者的住院费用减少 23%。